Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bovine LH superagonist is a recombinant protein analog of bovine luteinizing hormone (bLH) developed by Trophogen. It is designed to act as a high-potency superagonist at the luteinizing hormone receptor (LHR). In cattle, LH signaling is essential for the formation and function of the corpus luteum, which secretes progesterone to maintain pregnancy. The superagonist is engineered to provide superior bioactivity and a longer half-life compared to native LH or human chorionic gonadotropin (hCG), thereby enhancing progesterone production and reducing early embryonic loss in beef and dairy cows. The program is currently in the preclinical stage of development for veterinary applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bovine LH superagonist.